Truist Financial Forecasts Strong Price Appreciation for Medpace (NASDAQ:MEDP) Stock

Medpace (NASDAQ:MEDP) had its price target upped by stock analysts at Truist Financial from $462.00 to $609.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s price target suggests a potential upside of 1.27% from the stock’s previous close.

A number of other analysts also recently issued reports on MEDP. Mizuho raised their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Robert W. Baird increased their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday. TD Cowen raised their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday. Finally, Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $560.92.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $601.38 on Friday. Medpace has a 1 year low of $373.00 and a 1 year high of $677.90. The company has a market cap of $17.18 billion, a P/E ratio of 35.25, a PEG ratio of 2.93 and a beta of 1.15. The stock’s fifty day moving average price is $492.09 and its 200-day moving average price is $494.49.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same period last year, the company earned $3.10 EPS. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts anticipate that Medpace will post 17.59 earnings per share for the current year.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Medpace

Institutional investors have recently made changes to their positions in the business. Ausbil Investment Management Ltd boosted its holdings in shares of Medpace by 5.5% in the second quarter. Ausbil Investment Management Ltd now owns 4,275 shares of the company’s stock worth $2,324,000 after buying an additional 221 shares during the last quarter. Handelsbanken Fonder AB increased its holdings in Medpace by 0.6% during the second quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company’s stock valued at $3,718,000 after buying an additional 40 shares during the last quarter. Allied Private Wealth LLC bought a new position in Medpace in the second quarter worth approximately $31,000. Polianta Ltd raised its position in Medpace by 21.4% in the second quarter. Polianta Ltd now owns 3,400 shares of the company’s stock worth $1,800,000 after acquiring an additional 600 shares during the period. Finally, 180 Wealth Advisors LLC bought a new position in Medpace in the second quarter worth approximately $201,000. Institutional investors own 77.98% of the company’s stock.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.